GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recursion Pharmaceuticals Inc (NAS:RXRX) » Definitions » 3-Year RORE %

Recursion Pharmaceuticals (Recursion Pharmaceuticals) 3-Year RORE % : 9.81% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Recursion Pharmaceuticals 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Recursion Pharmaceuticals's 3-Year RORE % for the quarter that ended in Dec. 2023 was 9.81%.

The industry rank for Recursion Pharmaceuticals's 3-Year RORE % or its related term are showing as below:

RXRX's 3-Year RORE % is ranked better than
73.01% of 1393 companies
in the Biotechnology industry
Industry Median: -5.96 vs RXRX: 9.81

Recursion Pharmaceuticals 3-Year RORE % Historical Data

The historical data trend for Recursion Pharmaceuticals's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recursion Pharmaceuticals 3-Year RORE % Chart

Recursion Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
3-Year RORE %
- - - 18.04 9.81

Recursion Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.04 16.47 11.68 11.34 9.81

Competitive Comparison of Recursion Pharmaceuticals's 3-Year RORE %

For the Biotechnology subindustry, Recursion Pharmaceuticals's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recursion Pharmaceuticals's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Recursion Pharmaceuticals's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Recursion Pharmaceuticals's 3-Year RORE % falls into.



Recursion Pharmaceuticals 3-Year RORE % Calculation

Recursion Pharmaceuticals's 3-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -1.57--1.167 )/( -4.107-0 )
=-0.403/-4.107
=9.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 3-year before.


Recursion Pharmaceuticals  (NAS:RXRX) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Recursion Pharmaceuticals 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Recursion Pharmaceuticals's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Recursion Pharmaceuticals (Recursion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
41 S Rio Grande Street, Salt Lake City,, UT, USA, 84101
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Executives
Michael Secora officer: Chief Financial Officer C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Shafique Virani officer: Chief Corp. Dev. Officer C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Dean Y Li director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Blake Borgeson director C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Christopher Gibson director, 10 percent owner, officer: Chief Executive Officer C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Tina Marriott Larson officer: President and COO C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Zavain Dar director C/O LUX CAPITAL MANAGEMENT, LLC, 1600 EL CAMINO REAL - SUITE 290, MENLO PARK CA 94025
Terry-ann Burrell director C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
David J Mauro officer: Chief Medical Officer 36 TERRELL DRIVE, WASHINGTON CROSS PA 18977
Mubadala Investment Co Pjsc 10 percent owner P.O. BOX 45005, ABU DHABI C0 00000
Peter Hebert other: Former 10% Owner C/O LUX VENTURES, 295 MADISON AVE, 24TH FLOOR, NEW YORK NY 10017
Lux Ventures Iv, L.p. other: Former 10% Owner 295 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10017
Lux Venture Partners Iv, Llc other: Former 10% Owner 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Lux Co-invest Partners, Llc other: Former 10% Owner C/O LUX CAPITAL, 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Lux Co-invest Opportunities, L.p. other: Former 10% Owner C/O LUX CAPITAL MANAGEMENT, 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010